source
- Biotech reverse mergers surge 1,600% in Q3, matching number of IPOs in 2026Biotech companies are turning to reverse mergers as a faster, less volatile route to the public markets. In the third quarter of 2026, 17 reverse mergers were completed or announced, a 1,600% incre…
- Moderna and Merck's mRNA cancer vaccine extends survival in phase 3 melanoma trialMerck and Moderna reported that their personalized mRNA cancer vaccine improved patient outcomes in a late-stage study. The phase 3 INTerpath-001 trial enrolled 1,137 patients who had surgery to r…